Jennifer, also known as, “Trie”, is an Associate Director in Medical Affairs for Jazz Pharmaceuticals, leading the Cannabinoid Science Education program. Trie has been working in the cannabinoid science space for nearly 7 years and was instrumental in building the content for CannabinoidClinical.com educational website and leads the Cannabinoid Education Working Group. Trie has presented to learners across the United States including scientific and healthcare providers, advocacy groups, medical societies, state government and policy making members, and beyond the US including the UN Commission on Narcotic Drugs. Prior to her current role, Trie was a Medical Science Liaison at Greenwich Biosciences, US subsidiary of GW Pharmaceuticals, providing scientific support to develop an FDA-approved cannabidiol therapy for the treatment of seizures associated with epilepsy. Trie received her Master of Science in Cellular and Molecular Biology from Saint Cloud State University and her PhD in Comparative and Molecular Biosciences at the University of Minnesota, School of Veterinary Medicine. Before graduate school, she spent several years working in academia performing laboratory research focused on neuroendocrinology.
Is it just pot and an inconsequential debate on changing the schedule of marijuana or is it much more? Are we talking about individual...
Lori Jane Gliha is an award winning investigative reporter with Scripps News. She is also the nation's expert in tracking pediatric fatalities due to...
How should law enforcement, fire, hazmat, and hospitals respond to exposure to chemicals and drugs. Should hazmat to sterilize the area where a bag...